Latest Docetaxel Stories

NORTHBROOK, Ill., June 5, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. ("Astellas"), a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the company has entered into a distribution agreement with Tecnofarma International Ltd. to distribute enzalutamide (XTANDI(®) in the U.S.) in Latin America, excluding Brazil, upon regulatory approvals in the various countries. Financial terms of the agreements were not disclosed. "We are pleased to initiate a...

- Data accepted as late-breaking, oral presentation at ASCO 2013 RIDGEFIELD, Conn., June 3, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced results from the Phase III LUME-Lung 1 study showing that the addition of the investigational oncology compound nintedanib* to docetaxel improved progression-free survival (PFS) - the primary endpoint - as a second-line treatment in patients with advanced non-small cell lung cancer (NSCLC) compared...

Data Demonstrate Evidence of Indoximod's Safety and Anti-Tumor Activity When Used in Combination with Other Anti-Cancer Agents in Metastatic Solid Tumors AMES, Iowa, June 3, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway. Indoximod was tested...

New trial results presented at American Society of Clinical Oncology (ASCO) 2013 represent first advance in almost a decade in overall survival for patients where initial chemotherapy has failed BURLINGTON, ON, June 3, 2013 /CNW/ - New research on Canada's number one cancer killer(1) is further proof that patients need personalized treatments targeted to their specific type of lung cancer for better outcomes.  Boehringer Ingelheim (Canada) Ltd. today announced highly anticipated...

~New indication provides physicians with option to be used earlier in treatment of the disease, with hope of delaying chemotherapy~ TORONTO, May 29, 2013 /CNW/ - Janssen Inc. announced today that Health Canada has approved the once-daily, oral medication ZYTIGA(®) (abiraterone acetate), for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who are asymptomatic or mildly symptomatic after failure of...

Expanding OGX-427 Clinical Development Program Demonstrates the Company's Commitment to Addressing the Challenge of Cancer Treatment Resistance BOTHELL, Wash. and VANCOUVER, British Columbia, May 22, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a leader in the development of novel therapeutics to target mechanisms of treatment resistance in cancer, today announced that four trials of its investigational compounds, custirsen and OGX-427, will be presented as...

At Six Months Post Launch, Almost One Third of Surveyed Urologists have Prescribed Xtandi in Clinical Practice, According to a New Report from BioTrends Research Group EXTON, Pa., May 6, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists and medical oncologists prescribed...

Conference call to be held on Thursday, May 2 at 4:30pm Eastern Time BOTHELL, Wash. and VANCOUVER, British Columbia, May 2, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an overview of clinical development activities for its two product candidates, custirsen and OGX-427, and announced first quarter 2013 financial results. OGX-427 Program Update In January 2013, the Company initiated the ORCA(TM) (Ongoing Studies Evaluating Treatment Resistance...

The OGX-427 ORCA(TM) Program Continues to Expand with Patient Enrollment Now Open for Second Phase 2 Trial of OGX-427 in Advanced Bladder Cancer BOTHELL, Wash. and VANCOUVER, British Columbia, April 30, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced initiation of the Borealis-2(TM) clinical trial, an investigator-sponsored, randomized Phase 2 trial evaluating OGX-427 in combination with docetaxel in patients with advanced or metastatic bladder...

EAST SETAUKET, N.Y., April 25, 2013 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT), reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere®). Details of the trial underway at an NCI-designated Comprehensive Cancer Center are available in the clinical trials registry: http://clinicaltrials.gov/show/NCT01837667. Dr....